Statistics

Total Visits

Views
Long-term (104-Week) Efficacy and Safety Profile of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients with Psoriatic Arthritis: Results from a Phase III, Randomized, Controlled Trial and Open-Label Extension (PALACE 1)83

Select a period of time:

Number of views in the range

Views
Long-term (104-Week) Efficacy and Safety Profile of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients with Psoriatic Arthritis: Results from a Phase III, Randomized, Controlled Trial and Open-Label Extension (PALACE 1)12

Views

Views
November 20253
December 20251
January 20262
February 20260
March 20263
April 20262
May 20261
Download CSV file
 untranslated
 untranslated

Top country views

Views
United States7
Brazil2
Aruba1
Morocco1
Venezuela1
 

Top cities views

Views
Ashburn1
Atibaia1
Barinas1
Los Angeles1
Meknes1
Oranjestad1
São Paulo1